Vitamin C (Ascorbic Acid) |
|
|
Clinical Trial: BVAIT: B-Vitamin Atherosclerosis Intervention Trial
This study is no longer recruiting patients.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Atherosclerosis | Drug: folic acid Drug: vitamin B12 Drug: vitamin B6 | Phase II Phase III |
MedlinePlus related topics: Vascular Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: B-Vitamin Atherosclerosis Intervention Trial (BVAIT)
Secondary Outcomes: change in coronary and abdominal aortic calcification; neurocognitive change
Expected Total Enrollment: 506
Study start: November 2000; Study completion: June 2005
The primary hypothesis to be tested is that daily vitamin B supplementation reduces progression of early atherosclerosis. Ultrasonography will be used to measure the rate of change in the thickness of the carotid artery and CT will be used to measure coronary and aortic calcium. The beneficial effects of vitamin B supplementation are expected to occur with or without a change in LDL-C levels.
A total of 506 men and women will be randomized to receive either 1) vitamin B supplementation consisting of folic acid 5mg, vitamin B12 0.4mg, and vitamin B6 50mg, or 2) a matching placebo. Participants will receive ultrasonography at baseline and every 6 months for 2.5 to 4.5 years, and CT scan at baseline and end of study (2.5 to 4.5 years).
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Male or female (postmenopausal)
- 40 years or older
- Fasting plasma homocysteine 8.5 micromoles per liter (µmol/L) or greater
Exclusion Criteria:
- Any clinical signs or symptoms of cardiovascular disease (CVD)
- Diabetes mellitus or fasting serum glucose 140 mg/dL or greater
- Triglyceride (TG) levels 500mg/dL or greater
- Serum creatinine greater than 1.6 mg/dL
- Uncontrolled hypertension (systolic blood pressure 160 mmHg or greater and/or diastolic blood pressure 100 mmHg or greater)
- Thyroid disease (untreated)
- Life threatening disease with prognosis less than 5 years
- Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug use, cocaine use)
Location Information
California
Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles, California, 90033, United States
Howard N. Hodis, MD, Principal Investigator, University of California, Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine
More Information
Record last reviewed: June 2005
Last Updated: June 16, 2005
Record first received: June 14, 2005
ClinicalTrials.gov Identifier: NCT00114400
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-06-21

Not Signed In -

